Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GREAT real-world study of garadacimab in hereditary angioedema
NL-OMON58463Phase 4Not yet recruiting
- Sponsor
- CSL Behring
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of garadacimab in hereditary angioedema (HAE), sponsored by CSL Behring. Primary endpoint: Incidence rate ratio of hereditary angioedema attacks. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
garadacimab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NL-OMON58463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58463.